GLP-1 analogs in the treatment of obesity

Metelska Aleksandra, Metelski Jakub, Sereda Dominika, Nieścior Hubert. GLP-1 analogs in the treatment of obesity. Journal of Education, Health and Sport. 2022;12(8):334-342. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2022.12.08.034

https://apcz.umk.pl/JEHS/article/view/JEHS.2022.12.08.034

https://zenodo.org/record/6969152

 

 

 

 

 

The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of December 21, 2021. No. The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of December 21, 2021. No. 32343.

Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical Culture Sciences (Field of Medical sciences and health sciences); Health Sciences (Field of Medical Sciences and Health Sciences).

 

Punkty Ministerialne z 2019 - aktualny rok 40 punktów. Załącznik do komunikatu Ministra Edukacji i Nauki z dnia 21 grudnia 2021 r. Lp. 32343. Posiada Unikatowy Identyfikator Czasopisma: 201159.

Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).

 

© The Authors 2022;

This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.

(http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

 

Received: 25.07.2022. Revised: 27.07.2022. Accepted: 06.08.2022.

 

 

 

 

 

GLP-1 analogs in the treatment of obesity

Metelska Aleksandra

ORCID: https://orcid.org/0000-0002-3166-1296

metelskaaleksandra@gmail.com

Provincial Specialist Hospital of the name Stefan Cardinal Wyszyński, Aleja Kraśnicka 100, 20-718 Lublin

Metelski Jakub

ORCID: https://orcid.org/0000-0002-7110-9332

jakub.metelski@o2.pl

Provincial Specialist Hospital of the name Stefan Cardinal Wyszyński, Aleja Kraśnicka 100, 20-718 Lublin

Sereda Dominika

ORCID: https://orcid.org/0000-0003-4189-1674

dominika.sereda1902@gmail.com
Independent Public Clinical Hospital No. 4 in Lublin, Jaczewskiego 8, 20-954 Lublin

Nieścior Hubert

ORCID: https://orcid.org/0000-0002-4709-4396

hniescior@gmail.com

Medical University of Lublin, Aleje Racławickie 1, 20-059 Lublin

 

 

 

 

 

Abstract

 

Introduction and purpose

 

Obesity is a chronic disease that causes the development of numerous complications such as cardiovascular disease, cancer and type 2 diabetes. The 2017 global nutrition report showed that 2 billion adults and 41 million children worldwide are overweight or obese. Due to the growing problem of obesity, pharmacotherapy is recommended in patients with BMI ≥30 kg / m2 or BMI> 27 kg / m2 with accompanying risk factors. The aim of the study is to discuss the role of GLP-1 analogues in the treatment of obesity.

 

Description of the state of knowledge 

 

GLP-1 receptor agonists that were initially related to the treatment of type 2 diabetes are now being used successfully in the treatment of obesity.

The GLP-1 hormone is released from intestinal enteroendocrine cells in response to an increase in glucose levels. Due to the wide neuroanatomical distribution of GLP-1R within the structures of the reward system, it is possible to suppress the need for food intake, which translates into a reduction in the amount of food consumed and a decrease in body weight. The most common side effects associated with the use of GLP-1 analogues include gastrointestinal symptoms such as nausea, vomiting, diarrhea and constipation, which rarely lead to discontinuation of treatment.

 

Summary

 

Numerous studies have shown that chronic systemic delivery of GLP-1 agonists led to weight loss and helped to maintain a lower body weight. Reduction in food intake is reported as the main mechanism. Discontinuation of the drug was associated with weight gain.

Key words: glucagon-like peptide-1; obesity; GLP-1 receptor expression; GLP-1R driven food-oriented behaviors